Acne is one of the most common reasons a patient opens a telehealth app, and most of that traffic never needs isotretinoin. But the minority who do — cystic, scarring, treatment-resistant acne — sit at the sharpest edge of remote prescribing risk in the whole dermatology category, because the drug is a confirmed teratogen with a documented psychiatric-safety signal, and the prescribing guardrails around it have tightened rather than loosened.
Why isotretinoin sits apart from the rest of the acne pathway
Most acne treatment fits comfortably into remote care: topical retinoids, benzoyl peroxide, oral antibiotics, the combined pill or co-cyprindiol for some patients. A photo-led consultation, a clear escalation path, and a repeat-prescribing cadence cover the bulk of cases discussed in our UK dermatology telehealth launch guide.
Isotretinoin doesn't fit that pattern. It's a systemic retinoid with a well-established teratogenic risk — severe fetal malformation if a patient becomes pregnant while taking it — plus a monitoring burden covering mood, liver function and lipids that outlasts a single consultation. Prescriber discretion applies throughout, but the starting point for any telehealth operator is that this is not a repeat-prescription drug you bolt onto a standard acne pathway.
The specialist-only shift, and what it means for telehealth
UK isotretinoin prescribing has historically sat with dermatologists in secondary care, with some shared-care arrangements allowing GPs to continue a specialist-initiated course. Following MHRA-led safety reviews examining psychiatric and neurological adverse effects, guidance has moved further toward initiation being restricted to, or closely supervised by, a consultant dermatologist — not opened up to generalist remote prescribers.
That direction of travel matters for anyone weighing a UK telehealth acne vertical. A generalist prescriber workforce — the model that works well for contraception, HRT or hair loss — is not the right clinical governance structure for isotretinoin. Operators considering this drug need either an in-house dermatologist or a formal referral relationship into specialist care, not a same-day GP consult.
Inside the Pregnancy Prevention Programme
For anyone who can become pregnant, isotretinoin sits inside a Pregnancy Prevention Programme (PPP): a negative pregnancy test before starting, effective contraception maintained before, during and after treatment, and ongoing pregnancy testing through the course. Patients are given standardised warning materials and a signed acknowledgement of the risks before a first prescription is issued.
Dispensing is deliberately tight, too — prescriptions are typically limited to a short supply and dispensed close to the date they're written, rather than the 28-day repeat cycle common elsewhere in telehealth. That's a different operational rhythm from most of what's covered in our clinical SOPs guide, and it needs its own protocol rather than a variant of an existing one.
Isotretinoin isn't a controlled drug, but treat it like the highest-risk item in your acne catalogue: specialist-level clinical oversight, a Pregnancy Prevention Programme on every pregnancy-capable patient, and dispensing that enforces short-dated prescriptions rather than a standard repeat cycle.
Psychiatric and neurological monitoring — the other side of the safety profile
The teratogenicity risk gets most of the attention, but the psychiatric-safety signal is the reason recent reviews happened at all. Mood change, low mood and, rarely, more serious psychiatric symptoms have been reported in association with isotretinoin, and current guidance asks prescribers to screen for psychiatric history before starting and to check in on mood through the course — for every patient, not only those who can become pregnant.
That's a genuinely different monitoring shape from the rest of a telehealth dermatology service, and it's one reason adverse-event handling for this drug deserves more structure than a standard side-effect FAQ. Our adverse event and pharmacovigilance guide and Yellow Card reporting workflow cover the reporting mechanics that should sit behind any isotretinoin pathway, whether you run it in-house or refer it out.
Three operating models, and why most platforms pick the third
Operators weighing this vertical generally land on one of three models. Build a full in-house dermatologist-led service, complete with PPP administration and psychiatric screening — resource-intensive, and only worth it at meaningful acne volume. Prescribe it through a generalist workforce anyway — a route we'd steer most operators away from, given where specialist-only guidance is heading. Or route confirmed isotretinoin candidates to an established dermatology partner while keeping everything else — mild-to-moderate acne, eczema, rosacea — in-house.
In our experience, most UK telehealth brands land on the third option. It keeps the acquisition funnel intact — patients still start in your service — without taking on a clinical governance burden that doesn't match the rest of the platform's prescribing model.
Most UK telehealth brands don't build an in-house isotretinoin pathway — they keep the acne funnel, refer the drug, and get the dispensing paperwork right for whichever route the patient ends up on.
Dispensing, monitoring cadence, and the paperwork trail
Whichever model an operator chooses, dispensing has to track the clinical protocol precisely: short-dated prescriptions, PPP acknowledgement on file before the first dispense, and a documented pregnancy-test result attached to the record before each pregnancy-capable patient's repeat. A dispensing partner unfamiliar with this pattern will either over-restrict (delaying patients who are compliant) or under-restrict (dispensing against a lapsed test), and neither is acceptable under GPhC standards.
Patients under 18 raise a further layer — competence and consent assessment matters here as much as anywhere else in the acne pathway, and our Gillick competence and consent guide covers how that assessment should be documented for a remote consultation.
Where PExpo fits: dispensing infrastructure for specialist-led pathways
PExpo doesn't provide the dermatologist workforce — that's a clinical staffing decision for the operator or their specialist partner. What PExpo's regulated dispensing layer supports is the paperwork-heavy side of a pathway like this: enforcing short-dated dispensing windows, holding PPP acknowledgement and test results against the patient record before a dispense goes ahead, and giving the superintendent pharmacist oversight of a protocol that doesn't behave like the rest of the catalogue.
For operators building or refining a dermatology vertical that needs to handle isotretinoin correctly — whether prescribed in-house by a specialist or referred out — that's the layer worth getting right before volume arrives, not after.
Isotretinoin is a small slice of most dermatology telehealth volume, but it carries a disproportionate share of the regulatory and reputational risk, which is exactly why it deserves a deliberate build-or-refer decision rather than a default one. Whatever you decide, the record-keeping and dispensing discipline underneath it needs to match specialist-level care, not the rest of the catalogue — see our wider dermatology launch guide and clinical SOPs guide for how the rest of the vertical fits together, or talk to us about your clinic's dispensing setup.
Frequently asked questions
Can a UK telehealth GP prescribe isotretinoin directly?
It's possible under some shared-care arrangements, but current guidance is moving toward initiation by, or under the close supervision of, a consultant dermatologist rather than a generalist telehealth workforce. Most operators route confirmed candidates to a specialist partner instead of prescribing it through a general acne pathway. Prescriber discretion and current MHRA guidance apply.
What is the Pregnancy Prevention Programme?
It's a structured safety protocol for anyone who can become pregnant while taking isotretinoin, covering a negative pregnancy test before starting, effective contraception through the course, ongoing pregnancy testing, and signed acknowledgement of the risks. Dispensing is typically restricted to short-dated prescriptions rather than a standard repeat cycle to keep the testing cadence current.
Is isotretinoin a controlled drug in the UK?
No — isotretinoin is not classified as a controlled drug under the Misuse of Drugs Act. Its risk profile comes from teratogenicity and a documented psychiatric-safety signal rather than dependence potential, which is why the safeguards around it (PPP, mood monitoring, specialist oversight) look different from controlled-drug protocols.
